Pfizer: lung cancer drug cuts risk of progression or death

(CercleFinance.com) - A drug developed by Pfizer helps reduce the risk of disease progression or death in patients with non-small cell lung cancer, according to the results of a Phase 3 study presented in the New England Journal of Medicine.


The drug, Lorbrena, was studied in 260 participants and was shown to reduce the risk of progression or death by 72% in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), the drugmaker said.

Lorbrena blocks the tumor mutations that drive resistance to current medications and to address brain metastases.

Pfizer said the data will be reviewed under a FDA's program and will be shared with other health authorities to seek approval for this indication.

Copyright (c) 2020 CercleFinance.com. All rights reserved.